Shanghai Junshi Biosciences Co., Ltd.
688180
Rangering i aksjer
#3910
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise... Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.
Aksjekurs
$4.54
Markedsverdi
$4.16B
Endring (1 dag)
-2.35%
Endring (1 år)
-16.02%
Land
CN
Handel Shanghai Junshi Biosciences Co., Ltd. (688180)
Kategori
Healthcare
Inntekter for Shanghai Junshi Biosciences Co., Ltd. (688180)
Inntekter i 2026 TTM: 0
Ifølge Shanghai Junshi Biosciences Co., Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Shanghai Junshi Biosciences Co., Ltd. fra 2014 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | $-146.26M | -21.36% |
| 2024 | $-185.99M | -47.16% |
| 2023 | $-352.00M | -9.24% |
| 2022 | $-387.83M | 314.29% |
| 2021 | $-93.61M | -63.43% |
| 2020 | $-256.01M | 132.54% |
| 2019 | $-110.09M | 5.51% |
| 2018 | $-104.34M | 111.65% |
| 2017 | $-49.30M | 160.78% |
| 2016 | $-18.90M | 108.99% |
| 2015 | $-9.05M | 128.89% |
| 2014 | $-3.95M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
